SecBot SecBot
8-K ·Filed Apr 1, 2026

FBRX

Forte Biosciences, Inc.
BEARISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001193125-26-135767
earnings-rerun-backfill
Actionable Insight ▼ Bearish

Monitor cash burn rate and upcoming clinical trial readouts in 2026; the recent capital raise may not be sufficient given the increased R&D spend and lack of revenue generation.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$24.86
T+0 close · Apr 1, 2026 · via day close
Latest settled
−14.24%
T+60 · $21.32
Vs SPY
−27.62%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 1 $24.86entry
  2. T+1 · 8mo ago +2.90%α +2.82% · $25.58
  3. T+5 · 7mo ago +36.36%α +32.60% · $33.90
  4. T+20 · 7mo ago +12.75%α +3.03% · $28.03
  5. T+60 · 5mo ago −14.24%α −27.62% · $21.32
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Forte Biosciences reported a net loss per share of $(4.71) for FY 2025, missing consensus estimates, with R&D expenses nearly tripling due to clinical trial advancement. This follows a recent $150M follow-on offering, raising concerns about capital efficiency.

Key Financial Metrics

EPS
−$4.71
est −$1.16 · -276.7%
Revenue
$0.00
est $0.00 · 0.0%
Rating
strong miss

Key Facts

  • Net loss per share was $(4.71) for FY 2025, missing consensus of $-1.16
  • R&D expenses increased to $58.2M from $21.2M in 2024 due to clinical trials
  • Cash and cash equivalents decreased to $77.0M from $93.4M in Q3 2025
  • Recent $150M follow-on offering completed just 12 days prior to earnings

Financial Impact

Net loss of $69.375M vs consensus expectations of $20.0M loss

epscashr&d_expenses

Risk Factors

  • High cash burn rate may necessitate additional capital raises
  • Clinical trial failures could further impact stock performance

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-135767
Document: d63145d8k.htm0001193125-26-135767
Document: 0001193125-26-135767-index-headers.html0001193125-26-135767
Document: 0001193125-26-135767-index.html0001193125-26-135767
Document: 0001193125-26-135767.txt0001193125-26-135767
8-K Data (Synthetic)0001193125-26-135767

Track record

15 reports on FBRX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry price pending
  3. Nov 4, 202612d ago SC 13G/A Bearish 4/10 No price data
  4. Sep 2, 202610w ago EFFECT Bearish 7/10 Entry $76.99 settles Nov 27
  5. Sep 2, 202610w ago EFFECT Bearish 6/10 Entry $76.99 settles Nov 27
  6. Aug 27, 202611w ago 25-NSE Bearish 9/10 Entry $76.99 settles Nov 20
  7. Jul 27, 202616w ago 8-K Bullish 8/10 Entry $76.50 No price data
  8. Jun 11, 202622w ago EFFECT Bearish 6/10 Entry $17.40 No price data
  9. Jun 5, 202623w ago S-3/A Bearish 6/10 Entry $15.67 No price data
  10. Jun 2, 202623w ago S-3 Bearish 6/10 Entry $17.00 to $76.99 ▼ −352.88% −350.38% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 9h 13m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026